Immunochemotherapy Boosts Survival in Esophageal Squamous Cell Carcinoma

Induction immunochemotherapy leads to higher conversion surgery rates and improved overall survival compared to induction chemotherapy in patients with initially unresectable esophageal squamous cell carcinoma. The immunochemotherapy cohort exhibited a notably superior conversion rate and higher pathological complete response rates, resulting in significantly better overall survival outcomes. This study suggests that immunochemotherapy alongside conversion surgery may offer a more effective treatment approach for patients with unresectable esophageal squamous cell carcinoma.